Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30174226 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL22837826 | 0.91 | KDM4E (0.56) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL22831321 | 0.89 | CHRNB2 (0.51) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL31623324 | 0.89 | CHRNB2 (0.51) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL21444471 | 0.81 | MAPT (0.60) | CHRNB2CHRNA4KDM4ELTA4HKEAP1 | |
| SCHEMBL16858365 | 0.80 | CHRNB2 (0.67) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL5025139 | 0.80 | CHRNB2 (0.67) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL8360713 | 0.80 | CHRNB2 (0.67) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL30862627 | 0.80 | CHRNB2 (0.67) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL255563 | 0.79 | KMT2A (0.54) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582963-B2 | Separation matrix and method of separation | CYTIVA BIOPROCESS R&D AB (SE) | 2026-03-24 | — | — | US | disclosed |
| EP-4142930-B1 | SEPARATION MATRIX AND METHOD OF SEPARATION | PURIDIFY LTD (GB) | 2024-05-08 | — | — | EP | disclosed |
| US-20230191368-A1 | Separation Matrix and Method of Separation | CYTIVA BIOPROCESS R&D AB (SE) | 2023-06-22 | — | — | US | disclosed |
| US-20210069692-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO-RAD LABORATORIES, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20200406232-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESIN | BIO-RAD LABORATORIES, INC. | 2020-12-31 | — | — | US | disclosed |
| US-20200406232-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESIN | BIO-RAD LABORATORIES, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200406232-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESIN | FCGRT, PBRM1, BCR | CHRNB2 2470/4885CHRNA4 1929/4885KDM4E 1451/4885 |
| US-20210069692-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | ABCG2, SLC7A1, MSR1 | CHRNB2 2691/4885CHRNA4 2081/4885KDM4E 3830/4885 |
| US-12582963-B2 | Separation matrix and method of separation | EPCAM, PA2G4, MAG | CHRNB2 1390/4885CHRNA4 586/4885KDM4E 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.